TIVICAY (dolutegravir) Tablets for Oral Use.

Name: TIVICAY (dolutegravir) Tablets for Oral Use. - South Delhi Pharma
Brand: simple

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

TIVICAY is a prescription medicine. TIVICAY is used for HIV infection Treatment.
INDICATIONS AND USAGE
TIVICAY is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and children aged 12 years and older and weighing at least 40 kg.
DOSAGE FORMS & STRENGTHS
Tablets: 50 mg
Manufactured By: ViiV Healthcare
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “TIVICAY (dolutegravir) Tablets for Oral Use” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category HIV

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Description

Dolutegravir (DTG), sold under the brand name Tivicay, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure.

Dolutegravir was approved for medical use in the United States in 2013. It is on the World Health Organization’s List of Essential Medicines. Abacavir/dolutegravir/lamivudine, a combination with abacavir and lamivudine is also available. As of 2019, the World Health Organization (WHO) recommends DTG as the first- and second-line treatment for all persons with HIV.